Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Humacyte, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 0.55 · gapped above the open, then crossed back over prior close. High/low 0.56 at 4:00 pm ET, 0.54 at 10:00 am ET.
166 institutional managers report a position in Humacyte, Inc. worth $59.2M between them, filed on form 13F for the quarter ending 2026-06-30. 18 of them hold 80% of it, the largest being Antipodes Partners Ltd at 13.32%.
141 more managers in the register
18 managers hold 80% of the $59.2M institutional base. The other 148 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
HUMA (Humacyte, Inc.) has 3 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TMO −0.14%, in healthcare.
via Alyeska Investment Group, L.P., Davidson Kempner Capital Management LP · 7.95% of HUMA, 10.96% of AIB
via Antipodes Partners Ltd · 13.34% of HUMA, 32.47% of B
via Antipodes Partners Ltd · 13.34% of HUMA, 16.55% of TECK
via Antipodes Partners Ltd · 13.34% of HUMA, 17.15% of NTR
via Alyeska Investment Group, L.P., Davidson Kempner Capital Management LP, Woodline Partners LP +2 more · 7.95% of HUMA, 6.35% of ELMT
via Alyeska Investment Group, L.P., GSA Capital Partners LLP, HRT Financial LLC · 7.95% of HUMA, 17.37% of PSQH
Managers holding a meaningful stake in HUMA also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.